Results 31 to 40 of about 87,925 (315)

Response to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report

Journal of Medical Case Reports, 2011
Introduction Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors.
Kang Yoon-Koo
doaj   +1 more source

Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

PLoS ONE, 2011
Challenges today concern chronic myeloid leukemia (CML) patients resistant to imatinib. There is growing evidence that imatinib-resistant leukemic cells present abnormal glucose metabolism but the impact on mitochondria has been neglected. Our work aimed
Jérome Kluza, Manel Jendoubi, Caroline Ballot, Abir Dammak, Aurélie Jonneaux, Thierry Idziorek, Sami Joha, Véronique Dauphin, Myriam Malet-Martino, Stéphane Balayssac, Patrice Maboudou, Gilbert Briand, Pierre Formstecher, Bruno Quesnel, Philippe Marchetti   +14 more
doaj   +1 more source

Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

New England Journal of Medicine, 2017
Background Imatinib, a selective BCR‐ABL1 kinase inhibitor, improved the prognosis for patients with chronic myeloid leukemia (CML). We conducted efficacy and safety analyses on the basis of more than 10 years of follow‐up in patients with CML who were ...
A. Hochhaus, R. Larson, F. Guilhot, J. Radich, S. Branford, T. Hughes, M. Baccarani, M. Deininger, F. Cervantes, Satoko Fujihara, C. Ortmann, H. Menssen, H. Kantarjian, S. O’Brien, B. Druker   +14 more
semanticscholar   +1 more source

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor

Cells, 2020
Metabolic reprogramming is a hallmark of cancer cells in response to targeted therapy. Decreased glycolytic activity with enhanced mitochondrial respiration secondary to imatinib has been shown in imatinib-sensitive gastrointestional stromal tumors (GIST)
Wen-Kuan Huang, Jiwei Gao, Ziqing Chen, Hao Shi, Juan Yuan, Huanhuan L. Cui, Chun-Nan Yeh, Robert Bränström, Catharina Larsson, Shuijie Li, Weng-Onn Lui   +10 more
doaj   +1 more source

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.

Blood Advances, 2020
Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), improves overall survival (OS), but the introduction of newer TKIs requires the definition of the optimal first-line TKI for newly diagnosed ...
C. Vener, R. Banzi, F. Ambrogi, Annalisa Ferrero, G. Saglio, G. Pravettoni, M. Sant   +6 more
semanticscholar   +1 more source

Predicting the correct dose in children: Role of computational Pediatric Physiological‐based pharmacokinetics modeling tools

CPT: Pharmacometrics &Systems Pharmacology, Volume 12, Issue 1, Page 13-26, January 2023., 2023
Abstract The pharmacokinetics (PKs) and safety of medications in particular groups can be predicted using the physiologically‐based pharmacokinetic (PBPK) model. Using the PBPK model may enable safe pediatric clinical trials and speed up the process of new drug research and development, especially for children, a population in which it is relatively ...
Xu Zhou, Jiening Dun, Xiao Chen, Bai Xiang, Yunjie Dang, Deying Cao   +5 more
wiley   +1 more source

Induction of autophagy has protective roles in imatinib-induced cardiotoxicity

Toxicology Reports, 2021
Cardiotoxicity is one of the severe adverse effects of chemotherapeutic agents. Imatinib was previously reported to induce cardiotoxicity. Autophagy is an intracellular bulk protein and organelle degradation process, but its roles in cardiac diseases are
Miyuki Kobara, Naseratun Nessa, Hiroe Toba, Tetsuo Nakata   +3 more
doaj  

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.

Journal of Clinical Oncology, 2016
PURPOSE We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term efficacy and safety outcomes of patients with chronic myeloid leukemia ...
J. Cortes, G. Saglio, H. Kantarjian, M. Baccarani, J. Mayer, C. Boqué, N. Shah, C. Chuah, L. Casanova, Brigid Bradley-Garelik, G. Manos, A. Hochhaus   +11 more
semanticscholar   +1 more source

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib

Gastroenterology Research and Practice, 2014
Purpose. This retrospective, nonrandomized study investigated the effect of imatinib rechallenge plus best supportive care (BSC) on overall survival after imatinib and sunitinib treatment for patients with locally advanced or metastatic gastrointestinal ...
Akira Sawaki, Tatsuo Kanda, Yoshito Komatsu, Toshirou Nishida   +3 more
doaj   +1 more source

Validation of ion mobility spectrometry ‐ mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase

Rapid Communications in Mass Spectrometry, EarlyView., 2021
Rationale The protein kinase FGFR1 regulates cellular processes in human development. As over‐activity of FGFR1 is implicated with cancer, effective inhibitors are in demand. Type I inhibitors, which bind to the active form of FGFR1, are less effective than type II inhibitors, which bind to the inactive form. Screening to distinguish between type I and
Helen S. Beeston, Tobias Klein, Richard A. Norman, Julie A. Tucker, Malcolm Anderson, Alison E. Ashcroft, Geoffrey A. Holdgate   +6 more
wiley   +1 more source